After a span of 18 years, last week India fundamentally altered the way it regulates prices of essential drugs by shifting to a market-based mechanism from a cost-based formula. The new method, would fi x a ceiling price for each drug under regulation. Firms selling above price caps would have to slash rates, those selling below would have to freeze rates at May 2012 rates. ET presents an IMS Health anlaysis of how top cos would be impacted by this new price regime.
